Reslizumab in an invasively ventilated patient with acute respiratory failure

J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2922-2923. doi: 10.1016/j.jaip.2019.05.019. Epub 2019 May 25.

Authors

Andreas Renner¹, Katharina Marth², Lilian Schäffl-Doweik³, Wolfgang Pohl²

Affiliations

¹ Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria. Electronic address: [email protected].
² Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria.
³ 2nd Medical Department with Cardiology and Intensive Care Medicine, KA Rudolfstiftung, Vienna, Austria.

PMID: 31136820
DOI: 10.1016/j.jaip.2019.05.019

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Disease
Anti-Asthmatic Agents / administration & dosage
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / complications
Asthma / drug therapy
Bronchodilator Agents
Female
Humans
Middle Aged
Pulmonary Disease, Chronic Obstructive / complications
Pulmonary Disease, Chronic Obstructive / drug therapy
Respiration, Artificial*
Respiratory Function Tests
Respiratory Insufficiency / complications
Respiratory Insufficiency / drug therapy*
Smokers

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Bronchodilator Agents
reslizumab